secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001171843-24-004270
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q2 revenue $4.2B +7%, non-GAAP EPS $0.61, raises full-year 2024 guidance
-----------------------------------------------------------------------------

- Revenue $4.2B (+7% USD, +11% local currency); GAAP loss $0.75/share, non-GAAP EPS $0.61.
- Generics grew 16% US, 8% Europe, 22% International; AUSTEDO US revenue $407M (+32%).
- Raised 2024 guidance: revenue $16.0-16.4B, non-GAAP EPS $2.30-2.50, adj. EBITDA $4.6-5.0B.
- Pipeline: duvakitug top-line now Q4 2024; olanzapine LAI positive Phase 3; SIMLANDI launch.
- Free cash flow $324M; $506M tax hit from Israeli Tax Authority settlement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000117184324004270/0001171843-24-004270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000117184324004270/f8k_073124.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer